Literature DB >> 3004546

Pharmacokinetics of enalapril in normal subjects and patients with renal impairment.

J G Kelly, G Doyle, J Donohue, M Laher, M J Vandenburg, W J Currie, W D Cooper.   

Abstract

The pharmacokinetics of enalaprilat were studied after administration of single and multiple doses of enalapril maleate to people with normal and impaired renal function. Renal impairment was associated with higher serum concentrations of enalaprilat, longer times to peak concentrations, slower decline of serum concentrations and with reduced urinary elimination. Urinary elimination of enalaprilat was closely related to renal function. In patients with severe renal impairment (GFR values below 30 ml min-1 1.73 m-2) significantly smaller doses of enalapril maleate will be required than in patients with normal or less severely impaired renal function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004546      PMCID: PMC1400811          DOI: 10.1111/j.1365-2125.1986.tb02823.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Digoxin metabolism in the elderly.

Authors:  G A Ewy; G G Kapadia; L Yao; M Lullin; F I Marcus
Journal:  Circulation       Date:  1969-04       Impact factor: 29.690

2.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

3.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

4.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

Authors:  D M Gross; C S Sweet; E H Ulm; E P Backlund; A A Morris; D Weitz; D L Bohn; H C Wenger; T C Vassil; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

5.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

6.  Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers.

Authors:  A E Till; H J Gomez; M Hichens; J A Bolognese; W R McNabb; B A Brooks; F Noormohamed; A F Lant
Journal:  Biopharm Drug Dispos       Date:  1984 Jul-Sep       Impact factor: 1.627

  6 in total
  23 in total

Review 1.  Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Authors:  D A Sica; T W Gehr; A Fernandez
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

4.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

5.  Lisinopril in hypertensive patients with and without renal failure.

Authors:  B A van Schaik; G G Geyskes; P Boer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

7.  Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.

Authors:  E G Bevan; G T McInnes; J C Aldigier; J J Conte; J P Grunfeld; S J Harper; B H Meyer; N Pauly; R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

8.  Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.

Authors:  G A Verpooten; P M Genissel; J R Thomas; M E De Broe
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

9.  Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.

Authors:  D A Sica; R E Cutler; R J Parmer; N F Ford
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 10.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.